CTI's Pixuvri fails in postapproval trial

CTI BioPharma Corp. (NASDAQ:CTIC) said Pixuvri pixantrone missed the primary endpoint in the postmarketing Phase III PIX306 trial to treat aggressive B-cell non-Hodgkin's lymphoma (NHL). The failure means PIX306 "has not met the specific obligations" of the drug's conditional approval in the EU, CEO Adam Craig told BioCentury.

The company said Pixuvri plus Rituxan rituximab failed to significantly improve progression-free survival (PFS) vs. Rituxan plus gemcitabine in PIX306. It did not provide specific data...